AKTS
Aktis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.20
+1.74%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 77.12x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 1.74x
- Price / sales
- 84.04x
- Price / cash flow
- -11.23x
Enterprise value
- Enterprise value
- $339.3M
- EV / sales
- 33.73x
- EV / EBITDA
- -4.36x
- EV / EBIT
- -3.89x
- Market cap
- $845.4M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026